Pathway Studio® is a complete research informatics solution that integrates proprietary knowledge with findings from published literature in an analytical framework to reveal molecular connections that summarize the state of current knowledge and power novel discovery. To learn more visit: www.pathwaystudio.com
Nature Reviews Molecular Cell Biology FOCUS ON METABOLISM
Cells rapidly adapt to changes in nutrient availability and integrate this information about their metabolic state to drive cellular processes. Unprecedented insights are being gained into the molecular basis of how metabolic pathways interface with cell biological processes and how this can be disrupted in metabolic disorders.
Pharma incubates without strings doi:10.1038/nbt0412-297b Pharma-sponsored laboratory spaces are undoubtedly helping biotechs start out cheaply, but there's something in it for the hosts as well. Full Text
Hemacord approval may foreshadow regulatory creep for HSC therapies doi:10.1038/nbt0412-304 The approval for the use of hematopoietic stem/progenitor cells isolated from human cord blood in allogeneic transplantation in certain blood disorders or malignancies has reignited the debate over whether such products need additional regulation. Full Text
Analysis of drug failures underscores value of robust phase 2 testing doi:10.1038/nm0412-477b A recent analysis emphasizes that companies are wiser to spend more resources working on fine-tuning their therapy in phase 2 to avoid late-stage failures. Full Text
An audience with Trevor Mundel doi:10.1038/nrd3720 Trevor Mundel, new President of Global Health at the Bill & Melinda Gates Foundation, discusses his plans for a high-throughput approach to translational research. Full Text
A super kind of cytokine doi:10.1038/scibx.2012.405 Two research teams have engineered a variant of interleukin (IL)-2 that shows a better antitumor response in mice than wild-type IL-2. The new variant, dubbed an IL-2 superkine, is licensed to Teva, which is planning further preclinical studies of the molecule. Full Text
Fresh from the Pipeline: Aflibercept doi:10.1038/nrd3700 Fusion protein that inhibits vascular endothelial growth factor signalling approved in the United States for the treatment of neovascular age-related macular degeneration. Full Text
From the analyst's couch: Rare diseases and orphan drugs doi:10.1038/nrd3654 This article discusses market trends in the development of drugs for rare diseases, which have increasingly been recognized as providing attractive opportunities for the biopharmaceutical industry. Full Text
Neuromuscular disorders: Troponin activator improves muscle function doi:10.1038/nrd3703 A small-molecule activator of the troponin complex increased skeletal muscle strength in a rodent model of neuromuscular disease. Full Text
Neurological disorders: A class of its own doi:10.1038/nrd3704 A potential new class of drugs offers enhanced selectivity and efficacy over the drugs that are currently used in the clinic to treat absence seizures. Full Text
Immunotherapy: Combinations that work doi:10.1038/nrc3250 Preclinical data support the strategy of combining tumour-targeted therapies with immune-stimulating agents. Full Text
Novel molecular targets for atrial fibrillation therapy doi:10.1038/nrd3682 This Review focuses on the mechanistic rationale for the development of new anti-atrial fibrillation drugs, on the molecular and structural motifs that they target and on the results obtained so far in experimental and clinical studies. Full Text
Combining immunotherapy and targeted therapies in cancer treatment doi:10.1038/nrc3237 This article outlines how combining targeted approaches, which inhibit molecular pathways that promote tumour growth and maintenance, with immunotherapy, which stimulates a host immune response that effectuates long-lived tumour destruction, could provide therapeutic synergy. Full Text
A proteomics approach for the identification and cloning of monoclonal antibodies from serum doi:10.1038/nbt.2167 Cheung et al. couple proteomics with next-generation sequencing of RNA from B cells to clone antibodies directly from the sera of immunized rabbits and mice, potentially advancing immunology and vaccinology research and the development of therapeutics. Full Text
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma doi:10.1038/nbt.2157 Pulido et al. identify specific tumor-associated antigens from tumor-derived virus-expressed cDNA libraries that can be used in combination to cure established melanoma in mice. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment